Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 1.00 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306004 | 0.78 | ADORA2A (0.65) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL25283774 | 0.77 | ADORA2A (0.62) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL13024472 | 0.77 | ADORA2A (0.62) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL20771276 | 0.77 | ADORA1 (0.62) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL19153433 | 0.74 | ADORA2A (0.59) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL21145512 | 0.73 | ADORA2A (0.57) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL25339234 | 0.73 | ADORA2A (0.57) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL9696233 | 0.73 | ADORA2A (0.62) | ADORA1ADORA2AKMT2A | |
| SCHEMBL30614468 | 0.73 | ADORA1 (0.57) | ADORA1ADORA2ACCR8KMT2AKDM4E | |
| SCHEMBL343400 | 0.73 | ADORA2A (0.57) | ADORA1ADORA2AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-1992007468-A1 | HERBICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ADORA1 3046/4885ADORA2A 1836/4885CCR8 3045/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ADORA1 4484/4885ADORA2A 4582/4885CCR8 1958/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | ADORA1 3046/4885ADORA2A 1836/4885CCR8 3045/4885 |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | ADORA1 3437/4885ADORA2A 3024/4885CCR8 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.